On November 7, Asieris Hong Kong and Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. (SPH Keyuan Trade) signed a strategic cooperation agreement at the 7th China International Import Expo. Upon approval of Asieris’ core product, APL-1702, the two companies will collaborate extensively on import agency, bonded zone services, warehousing, logistics, and distribution. This partnership aims to harness their combined strengths to accelerate the commercialization of APL-1702, bringing swift benefits to patients in China.
APL-1702 from Asieris is the world’s first non-invasive treatment for precancerous cervical lesions, with its efficacy proven in a global Phase III clinical trial. As an alternative to the “one-size-fits-all” surgical approach, APL-1702 fulfills a crucial need for non-invasive treatment of precancerous cervical lesions by potentially reversing disease progression and minimizing recurrence. It contributes to cervical cancer elimination while safeguarding fertility, transforming care with a non-invasive approach that maintains cervical integrity. The new drug application for APL-1702 was accepted by the National Medical Products Administration in May 2024.
Chu Chenxi, Chairman and General Manager of SPH Keyuan Trade, said, “Asieris’ dedication to innovation aligns perfectly with our own, and we’re thrilled to help bring this pioneering therapy to patients faster. At SPH Keyuan Trade, we’re ready to share our resources and expertise with Asieris, providing top-tier support to our partner. Together, we aim to deliver the world’s first non-invasive treatment for precancerous cervical lesions to patients in China as quickly as possible.”
Sophia Cao, Senior Vice President of Asieris and Head of the Women’s Health Business Unit, said, “The new drug application for APL-1702 has been accepted, and we’re making strong progress in facilitating the review and approval process. By building external partnerships, we’re committed to fast-tracking the launch of innovative treatments and expanding patient access. SPH Keyuan Trade brings extensive expertise in commercialization, from drug imports to distribution. We’re excited to partner with this industry leader to rapidly deliver our pioneering treatment to benefit patients with precancerous cervical lesions.”
Attending the signing ceremony were Chu Chenxi, Chairman and General Manager of SPH Keyuan Trade; Zhang Lin, Assistant General Manager of SPH Keyuan Trade; Sophia Cao, Senior Vice President of Asieris and Head of the Women’s Health Business Unit; and Guo Hui, Senior National Commercial Director of Asieris.
About SPH Keyuan Trade
SPH Keyuan Trade is a key pharma import and distribution arm of Shanghai Pharma Holdings, a subsidiary of Shanghai Pharma Group, which has been consistently listed in the Fortune Global 500. As a large-scale, service-oriented pharma company, it offers a range of diversified services, including bonded import, pharmaceutical distribution, vaccine services, digital marketing, market access, and supply chain extension. The company delivers one-stop import solutions to many renowned global pharmaceutical companies, importing over 230 drug and vaccine specifications. With a distribution network spanning 31 provinces, municipalities, and autonomous regions in China, it connects to more than 1,300 distributors, over 2,300 disease prevention and control centers at the district or county level, and more than 100,000 retail pharmacies. With its vast resources and professional capabilities, SPH Keyuan Trade is committed to delivering high-quality services to international clients.
About Asieris Hong Kong
Asieris Hong Kong is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and women’s health. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
